Anti-Human LAG3 Recombinant Antibody (TSR-033) (CAT#: TAB-0367CL)

Figure 1 TSR-033 binds with high affinity to human and cyno LAG-3.

TSR-033 binds human and cyno LAG-3 expressed on the surface of CHO-S cells, but not mouse LAG-3, as assessed and flow cytometry.

Ghosh, S., Sharma, G., Travers, J., Kumar, S., Choi, J., Jun, H. T., ... & Jenkins, D. (2019). TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo. Molecular cancer therapeutics, 18(3), 632-641.

Figure 2 TSR-033 amplifies T cell effector function, particularly in combination with anti-PD-1.

The functional activity of TSR-033 was evaluated in an MLR assay, in which primary human CD4 T cells were mixed with monocyte-derived dendritic cells from a different donor. The ability of TSR-033 and TSR-042 to induce IL-2 from human PBMCs (n=5 donors) stimulated with 100 ng/mL SEB for 3 days was assessed. Data are representative of at least two separate occasions.

Ghosh, S., Sharma, G., Travers, J., Kumar, S., Choi, J., Jun, H. T., ... & Jenkins, D. (2019). TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo. Molecular cancer therapeutics, 18(3), 632-641.

Figure 3 Dual blockade of LAG-3 and PD-1 using TSR-033 and TSR-042 improves therapeutic efficacy and T cell stimulation in a humanized NSCLC tumor mouse model.

The combination of TSR-033 with TSR-042 has an additive effect (CDI=1.001) on restricting tumor growth in HuNOG-EXL mice inoculated with A549 cells. Mice were randomized at tumor volumes of 80-120 mm³, followed by administration of the indicated regimens (Materials and methods). Tumor growth inhibition at termination for each treatment arm is indicated in parentheses.

Ghosh, S., Sharma, G., Travers, J., Kumar, S., Choi, J., Jun, H. T., ... & Jenkins, D. (2019). TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo. Molecular cancer therapeutics, 18(3), 632-641.

Figure 1 Anti-Human LAG3 Recombinant Antibody (TAB-0367CL) in WB

Western blot analysis of TAB-0367CL was performed with Human LAG3 Protein (His Tag) in reduced condition Lane 1, Lane 2, Lane 3 (0.1 μg, 0.3 μg, 0.6 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-0367CL (2 ng/μL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Figure 2 Anti-Human LAG3 Recombinant Antibody (TAB-0367CL) in ELISA

ELISA analysis of TAB-0367CL was performed by coating with Human LAG3 Protein (His Tag). Then blocked with BSA and incubated with TAB-0367CL. The HRP-conjugated goat anti-human IgG was used as a secondary antibody (1:2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.